ANNX Jul 2024 12.500 call
| Previous Close | 0.2000 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 0.2000 |
| Strike | 12.50 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.2000 - 0.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 13 |
ZacksIs Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
GlobeNewswireAnnexon Announces Pricing of $125 Million Underwritten Public Offering
BRISBANE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of $6.25 per share and, in lieu of common stock to certain
ZacksAnnexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.
